IBM (NYSE: IBM), its Research Alliance partners GLOBALFOUNDRIES and Samsung, and equipment suppliers have developed an industry-first process to build silicon nanosheet transistors that will...

The Diamond Producers Association (DPA) announced today at the JCK show that their 2017 full-year marketing investment of $57 million has been released by the Board of Directors. Building on the...

Encouraging results from a Phase 2 randomized, multi-center clinical trial in pancreas cancer patients conducted by Halozyme Therapeutics (NASDAQ: HALO) were presented today at the American...

Janssen Research & Development, LLC today announced new data from updated analyses of the pivotal Phase 3 CASTOR and POLLUX clinical studies, demonstrating that DARZALEX® (daratumumab) in...

Oral presentation provides first REGN2810 data in patients with advanced cutaneous squamous cell carcinoma (CSCC) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive...

Sanofi and Regeneron Pharmaceuticals, Inc. today announced positive preliminary results with investigational REGN2810, a checkpoint inhibitor targeting PD-1 (programmed death 1), in patients with...

The first International Style Conference was jointly held in Niccolo Chengdu by T China and Chengdu International Finance Square (Chengdu IFS), dedicated to explore Style Transformation in China...

Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 '264 study that demonstrated IMLYGIC® (talimogene laherparepvec) in combination with the immune checkpoint inhibitor YERVOY®...

Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima®), a multiple receptor tyrosine kinase...

Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, presented the first efficacy data for an LpxC...